UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, announced that it has acquired exclusive rights to a gene therapy targeting GUCY2D-associated Leber congenital amaurosis (LCA1), a genetic eye disease that affects the retina and is a leading cause of blindness … Continue reading Atsena Therapeutics Acquires Exclusive Rights to Gene Therapy for GUCY2D-Associated Leber Congenital Amaurosis